Adaptimmune Therapeutics PLC ADAPY
0.03
0.01
50.00%
as of 25 Sep
- Market cap
- $14.6M
- P/E
- 0.0×
Follow ADAPY
| Older periods | Dec '24 | Mar '25 | Jun '25 | Dec '25 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(273.57%) | 1,087.18% | (1,349.52%) | — | |
| (27.17%) | (34.11%) | (75.53%) | 0.00% | ||
ROIC |
0.00% | 0.00% | 0.00% | — | |
Return on Tangible Assets |
(46.83%) | (86.91%) | (311.98%) | — | |
Average Days of Receivables |
29.49 | 8.90 | 52.23 | — | |
Free Cash Flow per Share |
(0.28) | (0.41) | (0.71) | — | |
Free Cash Flow |
(71.02) | (105.74) | (187.58) | — | |
Capital Expenditures |
(1.90) | (1.99) | (1.64) | — | |
Piotroski F-Score |
4.00 | 2.00 | 0.00 | — | |
| Other line items | |||||
Cash ROIC |
(32.16%) | (218.23%) | 967.31% | — | |
Accounts Receivable Turnover |
23.42 | 28.10 | 11.18 | — | |
Accounts Payable Turnover |
0.00 | 1.28 | 1.00 | — | |
Inventory Turnover |
— | 0.00 | 0.00 | — | |
Average Days of Payables |
0.00 | 264.91 | 404.69 | — | |
Days of Inventory on Hand |
0.00 | 546.40 | 490.32 | — | |
Tax Rate |
(0.03) | (0.03) | (0.02) | — | |
Research and Development Expense of Revenue |
62.70% | 58.61% | 134.92% | — | |
Selling, General and Administrative Expense of Revenue |
37.46% | 39.10% | 107.00% | — | |
Share Based Compensation of Revenue |
6.14% | 4.73% | 10.38% | — | |
Interest Coverage |
0.00 | 0.00 | 0.00 | — | |
Operating CF/Net income |
0.96 | 1.46 | 1.09 | — | |
Depreciation/Fixed assets |
0.51 | 0.53 | 0.55 | — | |
Capex/Depreciation |
(0.12) | (0.13) | (0.11) | — | |
Revenue per Share |
0.71 | 0.70 | 0.25 | — | |
Operating CF per Share |
(0.27) | (0.40) | (0.70) | — | |
Capex per Share |
(0.01) | (0.01) | (0.01) | — | |
Capex to Sales |
0.01 | 0.01 | 0.03 | — | |
Net Profit Margin |
(40.37%) | (39.50%) | (262.46%) | — |
Columns are period end dates